Not available
Quote | Second Sight Medical Products Inc. (NASDAQ:EYES)
Last: | $4.14 |
---|---|
Change Percent: | 123.78% |
Open: | $4.34 |
Close: | $1.85 |
High: | $4.35 |
Low: | $4.14 |
Volume: | 36,402 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Second Sight Medical Products Inc. (NASDAQ:EYES)
Gainers: GigaCloud Technology Inc Class A Ordinary Shares ( GCT ) +173% . Volcon ( VLCN ) +74% . Axsome Therapeutics ( AXSM ) +40% . Endo International plc ( ENDP ) +24% . Foot Locker ( FL ) +21% . Summit Therapeutics ( ...
Second Sight Medical Products, Inc. ( NASDAQ: EYES ), a maker of implantable visual prosthetics, dropped ~17% on Friday morning as its shares began trading on a split-adjusted basis following a 1-for-3 reverse stock split. In July, the company filed for an amendment to...
Message Board Posts | Second Sight Medical Products Inc. (NASDAQ:EYES)
Subject | By | Source | When |
---|---|---|---|
$EYES revoked: | Renee | investorshub | 11/27/2012 2:33:25 PM |
GREY MKT | Kobe Ginobili | investorshub | 09/23/2012 10:24:12 PM |
$EYES: SEC ADMIN Proceeding: | Renee | investorshub | 09/05/2012 10:28:08 PM |
Great stock symbol name | TRUSTUNITS | investorshub | 09/02/2012 8:27:42 PM |
EYES SEC Suspension: | Renee | investorshub | 05/15/2012 12:29:43 AM |
News, Short Squeeze, Breakout and More Instantly...
Second Sight Medical Products Inc. Company Name:
EYES Stock Symbol:
NASDAQ Market:
Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of u...
Grant proceeds support an ongoing early feasibility study of Orion Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prostheses that are intended to create an artificial for...
Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight”), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. (“NPM”)...